Avrobio and Eidos Therapeutics, rare disease drug developers on opposite sides of the country, have filed for initial public offerings, each company aiming to raise cash to finance more clinical tests of its lead drug.
Cambridge, MA-based Avrobio set a preliminary $86 million target for its IPO, according to its prospectus filed Friday. The gene therapy developer has applied for a listing on the Nasdaq under the stock symbol “AVRO.” Eidos Therapeutics of San Francisco, which develops treatments for a family of rare diseases linked to the buildup of a certain protein in the body, set an initial IPO goal of… Read more »
UNDERWRITERS AND PARTNERS